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Background
The availability of controller therapies at multiple
strengths is important to treat different severities of
asthma (NHLBI and GINA guidelines). The clinical
effect of medium-dose mometasone furoate/formoterol
(MF/F) combination administered via single inhaler had
never been characterized in asthmatic subjects versus
placebo. We investigated the effect of medium-dose
MF/F administered via an MDI on asthma deteriora-
tions (ie, severe asthma exacerbations) and pulmonary
function in moderately-severe asthmatics inadequately-
controlled on medium-dose inhaled corticosteroids
(ICS) ± long-acting b2-agonists (LABA).
Materials and methods
After 2-3-weeks open-label run-in with MF 200μgB I D ,
subjects (≥12 years) were randomized to 26-weeks treat-
ment BID with MF/F 200/10μg, MF 200μg, F 10μg, or
placebo. Coprimary endpoints were time-to-first asthma
deterioration over the treatment period (MF/F vs F),
and the area under the curve (AUC) of the change in
serial FEV1 [0-12 hr] to Week 12 (MF/F vs MF).
Results
781 subjects (mean: age=42.4 y, asthma duration=16.07
y, FEV1 % predicted=72.62%, reversibility=18.80%, ACQ
score=1.51) were randomized. MF/F increased the time-
to-first asthma deterioration and decreased the propor-
tion of subjects who experienced asthma deteriorations
(MF/F=30.4%; MF=33.9% [p=0.565]; F=54.0% [p<0.001];
placebo=55.6% [p<0.001]).M F / Ft r e a t m e n ti m p r o v e d
lung function more than MF within 5 minutes following
administration (p<0.001); mean Week-12 FEV1AUC0-12h
(L x h over baseline): MF/F=3.11, MF=1.30, F=1.93, and
placebo=0.57 (effect was maintained throughout the
treatment period). Adverse events were rare and similar
across treatment groups.
Conclusions
MF/F 200/10μg was more effective in reducing asthma
deteriorations and improving lung function in asth-
matics uncontrolled on medium-dose ICS±LABA than
placebo, MF or F.
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